TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $431,364 | +93.8% | 48,251 | +387.5% | 0.00% | – |
| Q1 2023 | $222,606 | -42.1% | 9,898 | -45.9% | 0.00% | -100.0% |
| Q4 2022 | $384,555 | -49.6% | 18,286 | -41.0% | 0.00% | -50.0% |
| Q3 2022 | $763,000 | +27.6% | 30,977 | +25.6% | 0.00% | +100.0% |
| Q2 2022 | $598,000 | -63.4% | 24,670 | -61.1% | 0.00% | -66.7% |
| Q1 2022 | $1,634,000 | -30.0% | 63,423 | -15.7% | 0.00% | -25.0% |
| Q4 2021 | $2,335,000 | +48.7% | 75,219 | +16.1% | 0.00% | +33.3% |
| Q3 2021 | $1,570,000 | +33.3% | 64,762 | -19.8% | 0.00% | +50.0% |
| Q2 2021 | $1,178,000 | +3.0% | 80,732 | +76.3% | 0.00% | 0.0% |
| Q1 2021 | $1,144,000 | +40.5% | 45,801 | +53.4% | 0.00% | +100.0% |
| Q4 2020 | $814,000 | – | 29,857 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |